From the early recognition of TILs as a surrogate of immune interactions in breast cancer (BC) and melanoma to the widespread use of PD-L1, these markers have shaped the landscape of decision making in Oncology and some of those have been incorporated as companion diagnostics by the regulatory authorities. This evidence concerns the gene CD274 and breast cancer.